Last Patient Completes Treatment in NTIPANS1 Clinical Trial
Filed with ASX · · 2 pages · English
Neurotech International Limited (ASX: NTI) (“Neurotech” or “the Company”), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces the successful completion of the LPLV for the Phase I/II clinical trial of NTI164 in children diagnosed with Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infect
Neurotech International Ltd. on 6ix
Story so far
Earlier from Neurotech International
- Appendix 4E & Annual Report
- First Patient Treated in Rett Syndrome Clinical Trial
- NTI Receives HREC Approval for Rett Syndrome Clinical Trial
- NTI Granted 2 Year Extension of Treatment for ASD Patients
- NTI granted HREC Approval for PANDAS/PANS Trial Extension
Later from Neurotech International
- Completion of Patient Recruitment in NTIRTT1 Clinical Trial
- Phase I/II PANDAS/PANS Clinical Trial Meets Primary Endpoint
- Neurotech Receives $3.17 Million R&D Tax Incentive Refund
- HREC Approval to Extend Phase II/III ASD Trial to Adults
- Phase II/III Autism Clinical Trial Completes Recruitment
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International